Significant regional disparities in HPV vaccine uptake threaten cervical cancer prevention goals, UKHSA warns.

The global market for Human Papillomavirus (HPV) Vaccines was estimated at US$5.5 Billion in 2024 and is projected to reach US$9.7 Billion by 2030, growing at a CAGR of 9.9% from 2024 to 2030.

The global Human Papillomavirus (HPV) Vaccines market, valued at USD 5.5 billion in 2024, is anticipated to grow to USD 9.7 billion by 2030 at a CAGR of 9.9%. This report offers comprehensive analysis ...

One of the most effective vaccines available was going to become more accessible—until RFK Jr. dismissed the CDC’s advisory ...

The global Human Papillomavirus (HPV) Vaccines market, valued at USD 5.5 billion in 2024, is anticipated to grow to USD 9.7 billion by 2030 at a CAGR ...

UKHSA data for 2023/24 in England shows inequalities in uptake of the jab in some regions. By Year 10, HPV coverage in girls was lowest in London (64.9%) and highest in the South East (82.7%).

YOUNG women are at higher risk of a “preventable” cancer due to “alarmingly” low uptake of life-saving NHS jabs, health chiefs have warned. Human papillomavirus (HPV) vaccin… ...

The HPV vaccine is one of the most powerful vaccines ever developed: It is unusual among immunizations in that it durably prevents infection and disease at rates close to 100 percent.

According to data published by Public Health Scotland, vaccine uptake among 12–13 year-olds in the least affluent areas has dropped to just 59.9%, compared to 82.1% in the most affluent.

Young women across certain regions of England are facing an elevated risk of cervical cancer, a direct consequence of alarmingly low uptake rates for the preventative human papillomavirus (HPV) ...